Personal Genome Diagnostics Collaborates with Merck on Global Clinical Trial Evaluating Response to Dual Biomarker Directed Precision Oncology Combination Therapy

On January 3, 2019 Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, reported that its 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (NSCLC) (KEYNOTE-495) (Press release, Personal Genome Diagnostics, JAN 3, 2019, View Source [SID1234532419]). This study will investigate the utility of biomarker-based triage for study participants with previously untreated advanced NSCLC. The PGDx elioTM tissue complete assay is being used during the enrollment process for the analysis of tumor mutational burden (TMB) status.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and TMB) will be randomized to receive pembrolizumab in combination with MK-4280 or lenvatinib. The study will involve more than 70 clinical sites worldwide.

"We are proud to collaborate with Merck on this trial. Merck is a leader in immune oncology and we view their selection of PGDx as a testament to our capabilities around TMB," said Doug Ward, Chief Executive Officer at PGDx. "With the kitted approach for the PGDx elio portfolio, we aim to expand patient access to comprehensive, local genomic testing and reduce turn-around time for results that inform critical treatment decisions for patients worldwide."

PGDx provides genomic solutions from biomarker discovery to companion diagnostic development through its CAP/CLIA certified laboratory and is developing a portfolio of regulated tissue-based and liquid biopsy genomic products to enable local next-generation sequencing (NGS) testing in laboratories worldwide.